Departamento de Química Inorgánica, Universidad Autónoma de Madrid, Francisco Tomas y Valiente 7, 28049 Madrid, Spain.
Eur J Med Chem. 2010 Jan;45(1):134-41. doi: 10.1016/j.ejmech.2009.09.035. Epub 2009 Oct 1.
Despite some initial research that reported a lack of activity of trans geometry, complexes with general formula trans-[PtCl2(L)(L')] exhibit an important cytotoxic activity in cisplatin-sensitive and resistant cell lines. Based on the proposed mechanism of action for the trans-platinum compounds, they might form DNA adducts initiating a DNA-damage response and ultimately ending in the activation of the p53 protein. In the present work, we have studied the biochemical properties of the trans-[PtCl2(isopropylamine)(L)] complexes (where L is 3- or 4-(hydroxymethyl)-pyridine) against several cell lines and the relationship between cytotoxicity and the protein p53. Both complexes showed different antitumoral properties depending on the presence or absence of protein p53 in isogenic colon carcinoma HCT116 cell lines. Cell cycle studies with the complexes in these cell lines were performed to investigate their antitumoral activity. Apoptosis was observed to be launched from G1 or G2/M accumulations. Confocal microscopy showed the different behaviour of isogenic tumoral cell lines treated with the trans-platinum complexes. Our data suggest that small differences in the carrier ligands could play an important role in the overall biological effects. The body of the research regarding structure-activity relationships such as the different position of groups in the carrier ligands will provide new rational basis for the design of new platinum antitumor drugs.
尽管最初的一些研究报告表明反式几何的活性缺乏,但具有通式反式-[PtCl2(L)(L')]的配合物在顺铂敏感和耐药细胞系中表现出重要的细胞毒性活性。基于反式铂化合物作用机制的研究,它们可能形成引发 DNA 损伤反应的 DNA 加合物,并最终导致 p53 蛋白的激活。在本工作中,我们研究了反式-[PtCl2(异丙胺)(L)]配合物(其中 L 是 3-或 4-(羟甲基)吡啶)对几种细胞系的生化特性以及细胞毒性与蛋白 p53 之间的关系。这两个配合物根据同源结肠癌细胞系 HCT116 中是否存在蛋白 p53,表现出不同的抗肿瘤特性。在这些细胞系中用这些配合物进行细胞周期研究,以研究它们的抗肿瘤活性。观察到细胞凋亡是从 G1 或 G2/M 积累开始的。共聚焦显微镜显示了用反式铂配合物处理的同源肿瘤细胞系的不同行为。我们的数据表明,载体配体中的微小差异可能在整体生物效应中发挥重要作用。关于结构-活性关系的研究,例如载体配体中基团的不同位置,将为设计新的铂类抗肿瘤药物提供新的合理基础。